| Protocol ID |
|
Title |
|
| Industry-breast |
|
A Prospective, Randomized, Double-Blind, Stratified, Placebo-Controlled, Multi-Center, 3-Arm Trial of the Continued Efficacy and Safety of Zometa® (Every 4 weeks vs. Every 12 weeks vs. Placebo) in Patients with Documented Bone Metastases From Breast Cancer
Keywords: bone metastases from breast cancer |
|
| TDM4370g |
|
A Randomized, Multicenter, Phase III, Open-Label Study of Efficacy and Safety of Trastuzumab-MCC-DM1 v. Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab-Based Therapy
Keywords: HER2-Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab-Based Therapy |
|
| ACOSOG Z1031 |
|
A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg) or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Keywords: postmenopausal women with state II or III estrogen receptor positive breast cancer |
|
| NSABP B-42 |
|
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Post-Menopausal Women with Hormone Receptor Positive Breast Cancer
Keywords: post-menopausal women with hormone receptor positive breast cancer |
|
| TAILORx |
|
PACCT-1: Program for the Assessment of Clinical Cancer Tests, a Trial Assigning IndividuaLized Options for Treatment (TAILORx)".
Keywords: individualized options for treatment |
|
| NSABP B-41 |
|
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2- Positive Breast Cancer Comparing the Combination of Trastuzumab plus Lapatibib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Keywords: Palpable and Operable HER2- Positive Breast Cancer |
|
| NSABP B-40 |
|
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered before AC or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with each of the Regimens
Keywords: Patients with Palpable and Operable Breast Cancer |
|
| NSABP B-43 |
|
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
Keywords: Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy |
|
| NCIC CTG MAP3 |
|
A Phase III Randomized Study of Exemestane vs Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Keywords: postmenopausal women at increased risk of developing breast cancer |
|
| EGF 108919 |
|
A Randomized, Open-Label, Phase III Study of Taxane based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/ neu Positive Metastatic Breast Cancer
Keywords: First-Line Therapy for Women with HER2/ neu Positive Metastatic Breast Cancer |
|
| RTOG/NSABP 0413 |
|
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Keywords: Stage 0, I, or II Breast Cancer |
|
| In-House |
|
Development of MRI Method to Measure Breast Tumor Blood Volume: A Sensitive and Specific Indicator of Breast Cancer
Keywords: Breast Cancer |